2017 Q1 Form 10-Q Financial Statement
#000119312517167391 Filed on May 11, 2017
Income Statement
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| Revenue | $13.70M | $16.21M |
| YoY Change | -15.46% | -15.98% |
| Cost Of Revenue | $692.0K | $761.0K |
| YoY Change | -9.07% | -44.93% |
| Gross Profit | $13.01M | $15.44M |
| YoY Change | -15.78% | -13.75% |
| Gross Profit Margin | 94.95% | 95.3% |
| Selling, General & Admin | $7.290M | $9.340M |
| YoY Change | -21.95% | -34.32% |
| % of Gross Profit | 56.05% | 60.48% |
| Research & Development | ||
| YoY Change | ||
| % of Gross Profit | ||
| Depreciation & Amortization | $470.0K | $480.0K |
| YoY Change | -2.08% | -20.27% |
| % of Gross Profit | 3.61% | 3.11% |
| Operating Expenses | $8.950M | $11.78M |
| YoY Change | -24.02% | -32.53% |
| Operating Profit | -$771.0K | -$1.187M |
| YoY Change | -35.05% | 316.49% |
| Interest Expense | $129.0K | $211.0K |
| YoY Change | -38.86% | -0.94% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $1.190M | $1.960M |
| YoY Change | -39.29% | |
| Pretax Income | -$898.0K | -$1.393M |
| YoY Change | -35.53% | 187.22% |
| Income Tax | -$8.000K | -$1.000K |
| % Of Pretax Income | ||
| Net Earnings | -$1.025M | -$1.835M |
| YoY Change | -44.14% | 346.47% |
| Net Earnings / Revenue | -7.48% | -11.32% |
| Basic Earnings Per Share | -$0.11 | -$0.19 |
| Diluted Earnings Per Share | -$0.11 | -$0.19 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 9.334M shares | 9.443M shares |
| Diluted Shares Outstanding | 9.334M shares | 9.443M shares |
Balance Sheet
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $11.20M | $3.900M |
| YoY Change | 187.18% | -20.41% |
| Cash & Equivalents | $11.24M | $3.889M |
| Short-Term Investments | ||
| Other Short-Term Assets | $3.800M | $2.400M |
| YoY Change | 58.33% | -60.66% |
| Inventory | $2.171M | $3.618M |
| Prepaid Expenses | ||
| Receivables | $6.300M | $8.500M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $23.49M | $18.41M |
| YoY Change | 27.6% | -26.15% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $10.68M | $21.85M |
| YoY Change | -51.12% | -3.03% |
| Goodwill | $461.0K | $461.0K |
| YoY Change | 0.0% | 0.0% |
| Intangibles | $2.589M | $2.731M |
| YoY Change | -5.2% | -4.94% |
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $908.0K | $1.463M |
| YoY Change | -37.94% | -3.88% |
| Total Long-Term Assets | $14.64M | $26.51M |
| YoY Change | -44.77% | -18.42% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $23.49M | $18.41M |
| Total Long-Term Assets | $14.64M | $26.51M |
| Total Assets | $38.13M | $44.92M |
| YoY Change | -15.11% | -21.78% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $1.851M | $4.975M |
| YoY Change | -62.79% | 12.33% |
| Accrued Expenses | $630.0K | $1.078M |
| YoY Change | -41.56% | -80.04% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $503.0K | $8.123M |
| YoY Change | -93.81% | 867.02% |
| Total Short-Term Liabilities | $6.640M | $19.06M |
| YoY Change | -65.16% | 78.14% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $6.327M | $3.321M |
| YoY Change | 90.51% | -71.06% |
| Other Long-Term Liabilities | $283.0K | $566.0K |
| YoY Change | -50.0% | -25.03% |
| Total Long-Term Liabilities | $7.489M | $5.104M |
| YoY Change | 46.73% | -61.39% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $6.640M | $19.06M |
| Total Long-Term Liabilities | $7.489M | $5.104M |
| Total Liabilities | $14.13M | $24.16M |
| YoY Change | -41.52% | 1.01% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | $6.744M | $2.882M |
| YoY Change | 134.0% | -81.57% |
| Common Stock | $17.68M | $18.25M |
| YoY Change | -3.13% | 0.28% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $24.00M | $20.80M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $38.13M | $44.92M |
| YoY Change | -15.11% | -21.78% |
Cashflow Statement
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$1.025M | -$1.835M |
| YoY Change | -44.14% | 346.47% |
| Depreciation, Depletion And Amortization | $470.0K | $480.0K |
| YoY Change | -2.08% | -20.27% |
| Cash From Operating Activities | -$1.090M | $630.0K |
| YoY Change | -273.02% | -52.99% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $289.0K | $302.0K |
| YoY Change | -4.3% | 17.05% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | $0.00 |
| YoY Change | ||
| Cash From Investing Activities | -$280.0K | -$340.0K |
| YoY Change | -17.65% | 30.77% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -1.770M | -130.0K |
| YoY Change | 1261.54% | -23.53% |
| NET CHANGE | ||
| Cash From Operating Activities | -1.090M | 630.0K |
| Cash From Investing Activities | -280.0K | -340.0K |
| Cash From Financing Activities | -1.770M | -130.0K |
| Net Change In Cash | -3.140M | 160.0K |
| YoY Change | -2062.5% | -82.42% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$1.090M | $630.0K |
| Capital Expenditures | $289.0K | $302.0K |
| Free Cash Flow | -$1.379M | $328.0K |
| YoY Change | -520.43% | -69.69% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
9162608 | shares |
| CY2015Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
4487000 | |
| CY2016Q1 | us-gaap |
Assets
Assets
|
44919000 | |
| CY2016Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
3455000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
3889000 | |
| CY2016Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
732000 | |
| CY2017Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2398000 | |
| CY2017Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
20986000 | |
| CY2017Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
9163000 | shares |
| CY2017Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
9163000 | shares |
| CY2017Q1 | us-gaap |
Assets
Assets
|
38133000 | |
| CY2017Q1 | us-gaap |
Assets Current
AssetsCurrent
|
23492000 | |
| CY2017Q1 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
10206000 | |
| CY2017Q1 | us-gaap |
Common Stock No Par Value
CommonStockNoParValue
|
||
| CY2017Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
13099000 | |
| CY2017Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
710000 | |
| CY2017Q1 | us-gaap |
Capital Lease Obligations
CapitalLeaseObligations
|
17000 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
11237000 | |
| CY2017Q1 | us-gaap |
Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
|
0 | |
| CY2017Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
4581000 | |
| CY2017Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1851000 | |
| CY2017Q1 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | |
| CY2017Q1 | us-gaap |
Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
|
0 | |
| CY2017Q1 | us-gaap |
Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
|
0 | |
| CY2017Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-420000 | |
| CY2017Q1 | us-gaap |
Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
|
0 | |
| CY2017Q1 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
7010000 | |
| CY2017Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
630000 | |
| CY2017Q1 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
11100000 | |
| CY2017Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
2000000 | shares |
| CY2017Q1 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
6327000 | |
| CY2017Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
7338000 | |
| CY2017Q1 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
503000 | |
| CY2017Q1 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
7489000 | |
| CY2017Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
2589000 | |
| CY2017Q1 | us-gaap |
Inventory Net
InventoryNet
|
2171000 | |
| CY2017Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
1258000 | |
| CY2017Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
38133000 | |
| CY2017Q1 | us-gaap |
Goodwill
Goodwill
|
461000 | |
| CY2017Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
283000 | |
| CY2017Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
6640000 | |
| CY2017Q1 | us-gaap |
Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
|
3958000 | |
| CY2017Q1 | us-gaap |
Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
|
0 | |
| CY2017Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
908000 | |
| CY2017Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2017Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
10683000 | |
| CY2017Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
31669000 | |
| CY2017Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
24004000 | |
| CY2017Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
6744000 | |
| CY2017Q1 | us-gaap |
Preferred Stock Share Subscriptions
PreferredStockShareSubscriptions
|
2000000 | shares |
| CY2017Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2784000 | |
| CY2017Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
1000000 | |
| CY2017Q1 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
508000 | |
| CY2017Q1 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
6300000 | |
| CY2017Q1 | ssy |
Professional Liability Risks Non Current
ProfessionalLiabilityRisksNonCurrent
|
879000 | |
| CY2015Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
5347000 | |
| CY2015Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5974000 | |
| CY2016Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2872000 | |
| CY2016Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
20920000 | |
| CY2016Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
9444000 | shares |
| CY2016Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
9444000 | shares |
| CY2016Q2 | us-gaap |
Assets
Assets
|
44105000 | |
| CY2016Q2 | us-gaap |
Assets Current
AssetsCurrent
|
17892000 | |
| CY2016Q2 | us-gaap |
Common Stock No Par Value
CommonStockNoParValue
|
||
| CY2016Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
13539000 | |
| CY2016Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
991000 | |
| CY2016Q2 | us-gaap |
Capital Lease Obligations
CapitalLeaseObligations
|
32000 | |
| CY2016Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
3261000 | |
| CY2016Q2 | us-gaap |
Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
|
1698000 | |
| CY2016Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
4722000 | |
| CY2016Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3391000 | |
| CY2016Q2 | us-gaap |
Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
|
624000 | |
| CY2016Q2 | us-gaap |
Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
|
7633000 | |
| CY2016Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-420000 | |
| CY2016Q2 | us-gaap |
Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
|
2461000 | |
| CY2016Q2 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
7157000 | |
| CY2016Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1883000 | |
| CY2016Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
2000000 | shares |
| CY2016Q2 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
2979000 | |
| CY2016Q2 | us-gaap |
Long Term Debt
LongTermDebt
|
11188000 | |
| CY2016Q2 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
7473000 | |
| CY2016Q2 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
4565000 | |
| CY2016Q2 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
2695000 | |
| CY2016Q2 | us-gaap |
Inventory Net
InventoryNet
|
2612000 | |
| CY2016Q2 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
1687000 | |
| CY2016Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
44105000 | |
| CY2016Q2 | us-gaap |
Goodwill
Goodwill
|
461000 | |
| CY2016Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
425000 | |
| CY2016Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
20051000 | |
| CY2016Q2 | us-gaap |
Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
|
13219000 | |
| CY2016Q2 | us-gaap |
Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
|
2745000 | |
| CY2016Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
732000 | |
| CY2016Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2016Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
12994000 | |
| CY2016Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
33914000 | |
| CY2016Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
19489000 | |
| CY2016Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
1648000 | |
| CY2016Q2 | us-gaap |
Preferred Stock Share Subscriptions
PreferredStockShareSubscriptions
|
2000000 | shares |
| CY2016Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2768000 | |
| CY2016Q2 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
0 | |
| CY2016Q2 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
736000 | |
| CY2016Q2 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
6166000 | |
| CY2016Q2 | ssy |
Professional Liability Risks Non Current
ProfessionalLiabilityRisksNonCurrent
|
1161000 | |
| CY2016Q4 | ssy |
Shareholder Threshold Percentage
ShareholderThresholdPercentage
|
0.049 | pure |
| dei |
Entity Registrant Name
EntityRegistrantName
|
SUNLINK HEALTH SYSTEMS INC | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.54 | ||
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1376000 | ||
| us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
-221000 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000096793 | ||
| us-gaap |
Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period
DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
|
2650000 | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-03-31 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
7976000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
59000 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--06-30 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.54 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
5096000 | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | ||
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
106000 | ||
| us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
15592000 | ||
| us-gaap |
Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
|
6937000 | ||
| us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
-15000 | ||
| us-gaap |
Cost Of Services
CostOfServices
|
2113000 | ||
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
342000 | ||
| us-gaap |
Interest Expense
InterestExpense
|
507000 | ||
| us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
|
0.46 | ||
| us-gaap |
Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
|
321000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4999000 | ||
| us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-243000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-5490000 | ||
| us-gaap |
Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
|
4287000 | ||
| us-gaap |
Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
|
1322000 | ||
| us-gaap |
Sales Revenue Net
SalesRevenueNet
|
41000000 | ||
| us-gaap |
Interest Paid
InterestPaid
|
458000 | ||
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
409000 | ||
| us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
17476000 | ||
| us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
0 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
5096000 | ||
| us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
4015000 | ||
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
640000 | ||
| us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
|
0.45 | ||
| us-gaap |
Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
|
14620000 | ||
| us-gaap |
Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
|
3019000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1696000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
18465000 | ||
| us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
141000 | ||
| us-gaap |
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
|
809000 | ||
| us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
0.09 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
573000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-236000 | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <b>Note 2. – Business Operations</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <u>Business Operations</u></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> SunLink owns businesses which are providers of healthcare services in certain <font style="WHITE-SPACE: nowrap">non-urban</font> markets in the United States. SunLink’s business is composed of the ownership of two business segments:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The Healthcare Facilities Segments, which is composed of:</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">A subsidiary which owns and operates an <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">84-licensed-bed,</font></font> acute care hospital, located in Houston, Mississippi, which includes an <font style="WHITE-SPACE: nowrap">18-bed</font> geriatric psychiatry unit (“GPU”) and a <font style="WHITE-SPACE: nowrap">66-bed</font> nursing home.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">A subsidiary which owns and operates a <font style="WHITE-SPACE: nowrap">100-bed</font> nursing home located in Ellijay, Georgia. This subsidiary also owns a hospital building and leases a portion of that building to an unaffiliated healthcare provider.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">A subsidiary which owns a medical office building and approximately two acres of unimproved land in Dahlonega, Georgia and a subsidiary which owns approximately 12 acres of unimproved land in Fulton, Missouri.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">A subsidiary which owns a closed hospital building and a medical office building in Clanton, Alabama, a portion of which is currently rented to an unaffiliated healthcare provider.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The Specialty Pharmacy Segment, which is composed of four operational areas:</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Pharmacy products and services which are conducted in rural markets at three locations in Louisiana;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Institutional pharmacy services consisting of the provision of specialty and <font style="WHITE-SPACE: nowrap">non-specialty</font> pharmaceutical and biological products to institutional clients or to patients in institutional settings, such as nursing homes, specialty hospitals, hospice, and correctional facilities;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Specialty pharmacy services; and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Durable medical equipment consisting primarily of products for nursing homes and patient-administered home care.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> SunLink subsidiaries have conducted the healthcare facilities business since 2001 and the specialty pharmacy operations since 2008. Our Specialty Pharmacy Segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of our SunLink ScriptsRx, LLC subsidiary.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The business strategy of SunLink is to focus its efforts on improving internal operations of the existing pharmacy business and healthcare facilities subsidiaries and on the sale or disposition of its subsidiaries’ underperforming assets. The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments and competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and by private payors, corporate strategy and other corporate objectives. The Company also is considering potential upgrades and improvements to certain of its healthcare facilities. The Company believes certain facilities in its Healthcare Facilities Segment as well as its Speciality Pharmacy Segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its specialty pharmacy business lines. The Company has used cash proceeds from recent dispositions of assets to pay off certain liabilities and to repurchase common shares in a tender offer completed in February 2017. The Company may use a portion of its existing cash, as well as any net proceeds from future dispositions, if any, to prepay debt, return capital to shareholders including through potential public or private purchases of share, make improvements to existing facilities, and for other general corporate purposes. There can be no assurance that any further dispositions, if any, will be authorized by the Company’s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Throughout these notes to the consolidated financial statements, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as “SunLink”, “we”, “our”, “ours”, “us” or the “Company.” This drafting style is not meant to indicate that SunLink Health Systems, Inc. or any particular subsidiary of SunLink Health Systems, Inc. owns or operates any asset, business, or property. The Trace Hospital, pharmacy operations and businesses described in this filing are owned and operated by distinct and indirect subsidiaries of SunLink Health System, Inc.</p> </div> | ||
| us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
2 | Segment | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1097000 | ||
| us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
0.09 | ||
| us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
4942000 | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
9429000 | shares | |
| us-gaap |
Supplies Expense
SuppliesExpense
|
1373000 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
9408000 | shares | |
| dei |
Trading Symbol
TradingSymbol
|
SSY | ||
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
3850000 | ||
| ssy |
Financial And Healthcare Services Revenue
FinancialAndHealthcareServicesRevenue
|
41321000 | ||
| ssy |
Payments To Acquire Property Plant And Equipment Continuing Operations
PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations
|
1097000 | ||
| ssy |
Payments To Acquire Property Plant And Equipment Discontinued Operations
PaymentsToAcquirePropertyPlantAndEquipmentDiscontinuedOperations
|
0 | ||
| ssy |
Net Operating Loss Carryforward Expiration Year
NetOperatingLossCarryforwardExpirationYear
|
2024 | ||
| ssy |
Number Of Hospital Facilities
NumberOfHospitalFacilities
|
4 | Hospital | |
| ssy |
Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
|
385000 | ||
| ssy |
Deposit Of Restricted Cash
DepositOfRestrictedCash
|
1000000 | ||
| us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
6210000 | ||
| us-gaap |
Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period
DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
|
0 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-2085000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
49000 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.36 | ||
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1356000 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.36 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-12849000 | ||
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
106000 | ||
| us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
15582000 | ||
| us-gaap |
Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
|
-1758000 | ||
| us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
641000 | ||
| us-gaap |
Cost Of Services
CostOfServices
|
2510000 | ||
| us-gaap |
Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
|
-1758000 | ||
| us-gaap |
Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
|
5898000 | ||
| us-gaap |
Sales Revenue Net
SalesRevenueNet
|
49373000 | ||
| us-gaap |
Interest Paid
InterestPaid
|
579000 | ||
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
582000 | ||
| us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
23918000 | ||
| us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
0 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-12849000 | ||
| us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
6125000 | ||
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
429000 | ||
| us-gaap |
Interest Expense
InterestExpense
|
637000 | ||
| us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
|
-0.19 | ||
| us-gaap |
Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
|
1461000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-291000 | ||
| us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-601000 | ||
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
0 | ||
| us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
|
-0.19 | ||
| us-gaap |
Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
|
0 | ||
| us-gaap |
Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
|
12000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3615000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1193000 | ||
| us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
78000 | ||
| us-gaap |
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
|
-11091000 | ||
| us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
-1.17 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-4240000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
6851000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1127000 | ||
| us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-1.17 | ||
| us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
0 | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
9443000 | shares | |
| us-gaap |
Supplies Expense
SuppliesExpense
|
2486000 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
9443000 | shares | |
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
601000 | ||
| ssy |
Financial And Healthcare Services Revenue
FinancialAndHealthcareServicesRevenue
|
50834000 | ||
| ssy |
Payments To Acquire Property Plant And Equipment Continuing Operations
PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations
|
1127000 | ||
| ssy |
Payments To Acquire Property Plant And Equipment Discontinued Operations
PaymentsToAcquirePropertyPlantAndEquipmentDiscontinuedOperations
|
66000 | ||
| ssy |
Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
|
-662000 | ||
| ssy |
Deposit Of Restricted Cash
DepositOfRestrictedCash
|
0 | ||
| CY2017Q1 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
-32000 | |
| CY2017Q1 | us-gaap |
Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period
DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
|
-75000 | |
| CY2017Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5000 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.11 | |
| CY2017Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
466000 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.11 | |
| CY2017Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-1025000 | |
| CY2017Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
35000 | |
| CY2017Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
5523000 | |
| CY2017Q1 | us-gaap |
Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
|
-210000 | |
| CY2017Q1 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
24000 | |
| CY2017Q1 | us-gaap |
Cost Of Services
CostOfServices
|
692000 | |
| CY2017Q1 | us-gaap |
Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
|
-135000 | |
| CY2017Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
|
318000 | |
| CY2017Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
13699000 | |
| CY2017Q1 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
142000 | |
| CY2017Q1 | us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
5872000 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
0 | |
| CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1025000 | |
| CY2017Q1 | us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
1194000 | |
| CY2017Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
126000 | |
| CY2017Q1 | us-gaap |
Interest Expense
InterestExpense
|
129000 | |
| CY2017Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
|
-0.01 | |
| CY2017Q1 | us-gaap |
Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
|
184000 | |
| CY2017Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | |
| CY2017Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
|
-0.01 | |
| CY2017Q1 | us-gaap |
Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
|
2000 | |
| CY2017Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-771000 | |
| CY2017Q1 | us-gaap |
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
|
-890000 | |
| CY2017Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
-0.10 | |
| CY2017Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-898000 | |
| CY2017Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-8000 | |
| CY2017Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
289000 | |
| CY2017Q1 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-0.10 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
9334000 | shares |
| CY2017Q1 | us-gaap |
Supplies Expense
SuppliesExpense
|
455000 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
9334000 | shares |
| CY2017Q1 | ssy |
Financial And Healthcare Services Revenue
FinancialAndHealthcareServicesRevenue
|
13883000 | |
| CY2017Q1 | ssy |
Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
|
38000 | |
| ssy |
Number Of Hospitals Sold
NumberOfHospitalsSold
|
3 | Hospital | |
| CY2016Q1 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
0 | |
| CY2016Q1 | us-gaap |
Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period
DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
|
0 | |
| CY2016Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
10000 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.19 | |
| CY2016Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
477000 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.19 | |
| CY2016Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-1835000 | |
| CY2016Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
35000 | |
| CY2016Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
5614000 | |
| CY2016Q1 | us-gaap |
Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
|
-443000 | |
| CY2016Q1 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
-1000 | |
| CY2016Q1 | us-gaap |
Cost Of Services
CostOfServices
|
761000 | |
| CY2016Q1 | us-gaap |
Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
|
-443000 | |
| CY2016Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
|
1844000 | |
| CY2016Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
16205000 | |
| CY2016Q1 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
191000 | |
| CY2016Q1 | us-gaap |
Labor And Related Expense
LaborAndRelatedExpense
|
7675000 | |
| CY2016Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
0 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1835000 | |
| CY2016Q1 | us-gaap |
Other Cost And Expense Operating
OtherCostAndExpenseOperating
|
1958000 | |
| CY2016Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
69000 | |
| CY2016Q1 | us-gaap |
Interest Expense
InterestExpense
|
211000 | |
| CY2016Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
|
-0.05 | |
| CY2016Q1 | us-gaap |
Health Care Organization Patient Service Revenue Provisionfor Bad Debts
HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts
|
213000 | |
| CY2016Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | |
| CY2016Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
|
-0.05 | |
| CY2016Q1 | us-gaap |
Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
|
5000 | |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1187000 | |
| CY2016Q1 | us-gaap |
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
|
-1392000 | |
| CY2016Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
-0.15 | |
| CY2016Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-1393000 | |
| CY2016Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-1000 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
302000 | |
| CY2016Q1 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-0.15 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
9443000 | shares |
| CY2016Q1 | us-gaap |
Supplies Expense
SuppliesExpense
|
647000 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
9443000 | shares |
| CY2016Q1 | ssy |
Financial And Healthcare Services Revenue
FinancialAndHealthcareServicesRevenue
|
16418000 | |
| CY2016Q1 | ssy |
Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
|
140000 |
